Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMS8H5Q)

Drug Name
NM-PP1 Drug Info
Synonyms
1-NM-PP1; 221244-14-0; PP1 Analog II, 1NM-PP1; 1-tert-butyl-3-(naphthalen-1-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; NM-PP1; Mutant Kinases Inhibitor II; 1NM-PP1(PP1 Analog II); AC1NP9I6; CHEMBL573578; 1 NM-PP1; CHEBI:52309; 4-Amino-1-tert-butyl-3-(1'-naphthylmethyl)pyrazolo[3,4-d]pyrimidine; 1-(tert-butyl)-3-(naphthalen-1-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; MMV676599; 1-(1,1-dimethylethyl)-3-(1-naphthalenylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; W-201917; C20H21N5
Cross-matching ID
PubChem CID
5154691
ChEBI ID
CHEMBL573578
CAS Number
CAS 221244-14-0
TTD Drug ID
D0GT8N

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Glycolysis / Gluconeogenesis 1.94 4.02e-2 56/67 (83.58%) ENO2;ALDH3A2;PKM;...
Ascorbate and aldarate metabolism 1.90 2.51e-2 15/30 (50%) ALDH3A2;AKR1A1;UGT2B17;...
Retinol metabolism 1.84 3.68e-2 41/68 (60.29%) ALDH1A2;UGT2B17;CYP26B1;...
Pyruvate metabolism 1.84 3.01e-2 41/47 (87.23%) ALDH3A2;PKM;AKR1A1;...
Primary bile acid biosynthesis 1.81 3.21e-2 15/17 (88.24%) AMACR;CYP27A1;SCP2;...
Tryptophan metabolism 1.77 4.35e-2 35/42 (83.33%) IDO1;ALDH3A2;ALDH2;...
Citrate cycle (TCA cycle) 1.76 3.73e-2 30/30 (100%) IDH1;PCK1;OGDH;...
Graft-versus-host disease 1.75 3.51e-2 32/42 (76.19%) HLA-B;PRF1;IL1A;...
Peroxisome 1.73 4.35e-2 72/82 (87.8%) ECI2;AMACR;SOD2;...
Allograft rejection 1.70 4.82e-2 32/38 (84.21%) HLA-B;PRF1;GZMB;...
Bile secretion 1.70 4.56e-2 68/90 (75.56%) KCNN2;SLC2A1;GNAS;...
Renin secretion 1.69 4.43e-2 61/69 (88.41%) KCNJ2;AGTR1;GNAI1;...
Mineral absorption -2.08 0.00e+0 48/60 (80%) ATP2B1;ATP1A1;SLC5A1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H